Author: Editor

Angela DeMichele, MD, MSCE, Co-Leader, Breast Cancer Research Program, Director, Breast Cancer Clinical Trials Unit, Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Alan and Jill Miller Professor in Breast Cancer Excellence from Penn Medicine and PennMedicine’s Abramson Cancer Center. In this video, she speaks about the SABCS 2021 Abstract – GS1-07 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial.

Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video, he discusses the article – Received a two-year, $240,000 grant from the American Cancer Society to study cytochrome c deficiency in African American men.   BUFFALO, New York — In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer health disparities.   African American…

Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video, he discusses the article – Received a two-year, $240,000 grant from the American Cancer Society to study cytochrome c deficiency in African American men.   BUFFALO, New York — In the United States, African American males have the highest prevalence of prostate cancer and the worst prognosis. Two Roswell Park Comprehensive Cancer Center teams will use new money from the US Department of Defense and the American Cancer Society to study and eliminate prostate cancer health disparities.   African American…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME). Origins:   Globally and in the United States, GEA is one of the main causes of cancer-related mortality. Therapeutic options for chemo-refractory GEA are limited, and effectiveness is low. PARP inhibitors have been shown to induce synthetic lethality and reduce tumor burden in in…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME). Origins:   Globally and in the United States, GEA is one of the main causes of cancer-related mortality. Therapeutic options for chemo-refractory GEA are limited, and effectiveness is low. PARP inhibitors have been shown to induce synthetic lethality and reduce tumor burden in…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract – Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. Origins:   Cabo is a multi-kinase inhibitory anti-VEGFR2/MET/AXL medication with a broad anti-VEGFR2/MET/AXL range. Cabo showed good immune modulatory action in preclinical and clinical tests in several solid malignancies, with clinical synergy evident when paired with PD-1/PD-L1 inhibitors…

Dr. Anwaar Saeed, MD, Associate Professor of Medicine, Division of Medical Oncology, Associate Director- Early Phase Program at University of Kansas Medical Center. In this video, she speaks about the ASCO GI 2022 Abstract – Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results. Origins:   Cabo is a multi-kinase inhibitory anti-VEGFR2/MET/AXL medication with a broad anti-VEGFR2/MET/AXL range. Cabo showed good immune modulatory action in preclinical and clinical tests in several solid malignancies, with clinical synergy evident when paired with PD-1/PD-L1 inhibitors…

John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he speaks about the ASCO GI 2022 Discussion – Tailoring Systemic and Local Therapies in Oligometastatic Cancer: A Case-Based Discussion.  

Orphan Drug Designation Update: IDEAYA Biosciences inc Darovasertib and Crizotinib Synthetic Lethal Combination Expansion Dose in Heavily Pre-Treated Metastatic Uveal Melanoma (MUM) * Press Release Update May 12, 2022 – IDE196 Darovasertib and crizotinib combination Orphan Drug Designation by FDA Darovasertib has been identified as an Orphan Drug Designation by the U.S. FDA, entitling IDEAYA to certain tax credits, exemption from user fees, and potential statutory marketing exclusivity. -  Targeting a clinical data update for darovasertib and crizotinib combination and FDA regulatory guidance for a potential registration-enabling trial design in mid-2022 SOUTH SAN FRANCISCO, Calif., May 2, 2022 /PRNewswire/ – IDEAYA…

Meredith McKean, MD, Sarah Cannon Research Institute at Tennessee Oncology, Associate Director, Melanoma and Skin Cancer Research speaks about IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma.IDEAYA Biosciences, Inc., a precision medicine oncology company focused on the discovery and development of targeted therapeutics, has provided a clinical data update for the Phase 1/2 trial evaluating the synthetic lethal combination of darovasertib and crizotinib in patients with metastatic uveal melanoma (MUM).There are presently no FDA-approved medicines for metastatic uveal melanoma or GNAQ/GNA11 solid tumors, indicating that there…

Professor Eric Van Cutsem, MD, Ph.D., is full professor and Division Head of Digestive Oncology at the University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium. In this interview, Professor Van Cutsem speaks about Comments on the DESTINY-Gastric02 trial from Enhertu.Brief Synopsis:Participants with stomach or gastroesophageal junction cancer will be enrolled in this trial to see if trastuzumab deruxtecan is safe and effective.They must have stomach or gastro-esophageal junction (GEJ) cancer that is human epidermal growth factor receptor 2 (HER2) positive:* that cannot be surgically removed* that has spread throughout the body* that deteriorated during or during trastuzumab treatmentA…

The DESTINY-Gastric02 study is a very important study because it’s the first study in western patients with HER2 positive Gastric or Gastroesophageal junction adenomas who were progressive on trastuzumab containing chemotherapy. And then, the patients were treated with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhurtu). This was a study Western in patients and it’s following the Gastric01 study, which was in Asian and Korean patients. This Gastric02 study was a phase two study. It’s a nonrandomized study and the primary endpoint. Is response rate objective response rate as evaluated by independent committee responses are important in this situation because this is…

Yelena Y. Janjigian, MD, Cheif, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. In this interview Dr. Janjigian speaks about the ASCO GI 2022 Abstract – Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.Origins:T-DXd is a humanized anti-HER2 monoclonal antibody with a tetrapeptide-based cleavable linker and a topoisomerase I inhibitor payload in an antibody-drug combination. T-DXd is approved in the United States and Israel for HER2+ advanced/metastatic GC/GEJA after a trastuzumab-based treatment, as well as GC after chemotherapy (Japan). In DESTINY-Gastric01, T-DXd outperformed…

Yelena Y. Janjigian, MD, Cheif, Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. In this interview Dr. Janjigian speaks about the ASCO GI 2022 Abstract – Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.Origins:T-DXd is a humanized anti-HER2 monoclonal antibody with a tetrapeptide-based cleavable linker and a topoisomerase I inhibitor payload in an antibody-drug combination. T-DXd is approved in the United States and Israel for HER2+ advanced/metastatic GC/GEJA after a trastuzumab-based treatment, as well as GC after chemotherapy (Japan). In DESTINY-Gastric01, T-DXd outperformed…

Dr. Michael Mauro, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center. In this video, he speaks about Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib.According to updated findings from the phase 3 ASCEMBL trial (NCT03106779) presented at the American Society of Hematology Annual Meeting & Exposition, chronic-phase chronic myeloid leukemia (CP-CML) treated with asciminib (Scemblix) was more likely to achieve major molecular response (MMR) than bosutinib (Bosulif) without any new or worsening adverse effects (AEs).The MMR rate at 48 weeks was 29.3 percent with asciminib vs 13.2 percent with bosutinib,…

Dr. Michael Mauro, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center. In this video, he speaks about Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib.According to updated findings from the phase 3 ASCEMBL trial (NCT03106779) presented at the American Society of Hematology Annual Meeting & Exposition, chronic-phase chronic myeloid leukemia (CP-CML) treated with asciminib (Scemblix) was more likely to achieve major molecular response (MMR) than bosutinib (Bosulif) without any new or worsening adverse effects (AEs).The MMR rate at 48 weeks was 29.3 percent with asciminib vs 13.2 percent with bosutinib,…

Dr. Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. In this interview, he speaks about the ASCO GI 2022 Abstract – Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.Context:T-DXd is an antibody-drug combination that targets HER2. T-DXd showed clinically meaningful improvements in objective response rate (ORR) and overall survival (OS) compared to chemotherapy in the primary…

Dr. Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. In this interview, he speaks about the ASCO GI 2022 Abstract – Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.Context:T-DXd is an antibody-drug combination that targets HER2. T-DXd showed clinically meaningful improvements in objective response rate (ORR) and overall survival (OS) compared to chemotherapy in the primary…

Richard Francis Dunne, MD, Assistant Professor – Department of Medicine, Hematology/Oncology (SMD) at the University of Rochester Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.Origins:In the CROSS study, it was discovered that neoadjuvant chemoradiotherapy (CRT) is given before surgery to patients with esophageal (E) and gastroesophageal junction (GEJ) malignancies improved survival. However, 10-year data did not suggest that minimizing isolated distant metastases was beneficial. Prior to CRT, adding full-dose induction chemotherapy (CT) could give…

Richard Francis Dunne, MD, Assistant Professor – Department of Medicine, Hematology/Oncology (SMD) at the University of Rochester Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.Origins:In the CROSS study, it was discovered that neoadjuvant chemoradiotherapy (CRT) is given before surgery to patients with esophageal (E) and gastroesophageal junction (GEJ) malignancies improved survival. However, 10-year data did not suggest that minimizing isolated distant metastases was beneficial. Prior to CRT, adding full-dose induction chemotherapy (CT) could give…

Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. In this video Dr. Schmidt speaks about the ASH 2021 Abstract – 467 Impact of Chromosome 1 Abnormalities Among Patients with…

Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. In this video Dr. Schmidt speaks about the ASH 2021 Abstract – 467 Impact of Chromosome 1 Abnormalities Among Patients with…

Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School & Resident Member at Rutgers Cancer Institute of New Jersey speaks about the ASH 2021 Abstract 2221 Sirt1 Is a Novel Therapeutic Target in T-ALL.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153950.htmlT-cell Acute Lymphoblastic Leukemia (T-ALL) is leukemia that affects both children and adults. Despite this, 20 percent to 50 percent of individuals develop initial resistance or relapse after treatment and eventually succumb to their illness. Because more than 60% of T-ALL individuals have to activate mutations in the NOTCH1 gene, abnormal NOTCH1 signaling plays a key…

Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School & Resident Member at Rutgers Cancer Institute of New Jersey speaks about the ASH 2021 Abstract 2221 Sirt1 Is a Novel Therapeutic Target in T-ALL.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153950.htmlT-cell Acute Lymphoblastic Leukemia (T-ALL) is leukemia that affects both children and adults. Despite this, 20 percent to 50 percent of individuals develop initial resistance or relapse after treatment and eventually succumb to their illness. Because more than 60% of T-ALL individuals have to activate mutations in the NOTCH1 gene, abnormal NOTCH1 signaling plays a key…

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Hope Rugo, MDSpeaks about Challenges and Opportunities for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Adam Brufsky, MD, Ph.D.Speaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case Studies

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeakers -Adam Brufsky, MD, Ph.D. – Interactive Case StudiesSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Oppotrunites for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeakers -Adam Brufsky, MD, Ph.D. – Interactive Case StudiesSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Oppotrunites for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Giampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive Biomarkers

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy Monitoring Speakers -Adam Brufsky, MD, PhDSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Opportunities for Optimizing Immunotherapies for TNBC

Peter Cole, MD, Rutgers Cancer Institute of New Jersey Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology and Chief of the Division of Pediatric Hematology/Oncology, also affiliated with Robert Wood Johnson University Hospital speaks about the ASH 2021 Abstract – 3485 Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152369.htmlOverview:In juvenile acute lymphoblastic leukemia, a sensitive and early assessment of minimal residual disease (MRD) is critical for risk classification (ALL). To detect MRD at the level of 1 leukemic cell in a…

Peter Cole, MD, Rutgers Cancer Institute of New Jersey Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology and Chief of the Division of Pediatric Hematology/Oncology, also affiliated with Robert Wood Johnson University Hospital speaks about the ASH 2021 Abstract – 3485 Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152369.htmlOverview:In juvenile acute lymphoblastic leukemia, a sensitive and early assessment of minimal residual disease (MRD) is critical for risk classification (ALL). To detect MRD at the level of 1 leukemic cell in a…

Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH 2021 Abstract 896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147915.htmlIntroduction:Teclistamab (JNJ-64007957) is a bispecific IgG4 T-cell redirection antibody that binds both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1, an ongoing phase 1/2 research in patients with extensively pretreated relapsed/refractory multiple myeloma, is testing teclistamab (RRMM). After a median of 6.1 months of follow-up, results from the phase…

Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH 2021 Abstract 896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147915.htmlIntroduction:Teclistamab (JNJ-64007957) is a bispecific IgG4 T-cell redirection antibody that binds both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1, an ongoing phase 1/2 research in patients with extensively pretreated relapsed/refractory multiple myeloma, is testing teclistamab (RRMM). After a median of 6.1 months of follow-up, results from the phase…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an adaptive strategy…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an adaptive strategy…

Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies.Link to Article:https://medicalxpress.com/news/2022-01-cancers-immune-archetypes-potential-approach.htmlLink to Study:https://authors.elsevier.com/c/1eJiWL7PXf0ZuSynopsisCancers differ significantly in terms of origin tissue, driver mutations, and other aspects of the surrounding tissue. Individual tumors are likely to engage common immune system patterns, or “archetypes,” to create prototype non-destructive tumor immune microenvironments (TMEs) and modulate tumor-targeting. The Immunoprofiler Initiative (IPI) at the University of California, San Francisco (UCSF) evaluated 364 unique tumors across 12 cancer types using standardized techniques to discover the…

Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies.Link to Article:https://medicalxpress.com/news/2022-01-cancers-immune-archetypes-potential-approach.htmlLink to Study:https://authors.elsevier.com/c/1eJiWL7PXf0ZuSynopsisCancers differ significantly in terms of origin tissue, driver mutations, and other aspects of the surrounding tissue. Individual tumors are likely to engage common immune system patterns, or “archetypes,” to create prototype non-destructive tumor immune microenvironments (TMEs) and modulate tumor-targeting. The Immunoprofiler Initiative (IPI) at the University of California, San Francisco (UCSF) evaluated 364 unique tumors across 12 cancer types using standardized techniques to discover the…

Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about the ASH 2021 Abstract 815 Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152976.htmlContext:E4402 was a randomized phase III trial that compared two alternative rituximab dosing techniques for individuals with low tumor burden follicular lymphoma who had previously been untreated (FL). The time to treatment failure was the primary outcome. The first study (Kahl, JCO 2014) found that a retreatment…

Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about the ASH 2021 Abstract 815 Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152976.htmlContext:E4402 was a randomized phase III trial that compared two alternative rituximab dosing techniques for individuals with low tumor burden follicular lymphoma who had previously been untreated (FL). The time to treatment failure was the primary outcome. The first study (Kahl, JCO 2014) found that a retreatment…

Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract – 413 Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149356.htmlIntroduction:The most effective anti-leukemia treatment after remission is allogeneic stem cell transplantation (alloSCT). However, the accompanying toxicity is a deterrent to its widespread use as standard of care in the elderly. Because randomized controlled trials comparing transplantation to non-transplantation are difficult to conduct, most studies of AML patients who had alloSCT are retrospective. The results of E2906,…

Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract – 413 Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149356.htmlIntroduction:The most effective anti-leukemia treatment after remission is allogeneic stem cell transplantation (alloSCT). However, the accompanying toxicity is a deterrent to its widespread use as standard of care in the elderly. Because randomized controlled trials comparing transplantation to non-transplantation are difficult to conduct, most studies of AML patients who had alloSCT are retrospective. The results of E2906,…

Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania speaks about the ASH 2021 Abstract 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects and 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies.Link to Abstract 163:https://ash.confex.com/ash/2021/webprogram/Paper151093.htmlLink to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT02030847Link to Abstract 253:https://ash.confex.com/ash/2021/webprogram/Paper153945.html

Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania speaks about the ASH 2021 Abstract 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects and 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies.Link to Abstract 163:https://ash.confex.com/ash/2021/webprogram/Paper151093.htmlLink to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT02030847Link to Abstract 253:https://ash.confex.com/ash/2021/webprogram/Paper153945.html

J. Joseph Melenhorst, Ph.D., Research Professor of Pathology and Laboratory Medicine Department: Pathology and Laboratory Medicine from the University of Pennsylvania speaks about the ASH 2021 Abstract 166 Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152664.htmlAdoptive transfer of chimeric antigen receptor (CAR)-reprogrammed T cells has shown promise in treating a variety of cancers. In chronic lymphocytic leukemia (CLL), functional persistence of CAR T-cells is a crucial predictor of long-term remissions, although the properties of long-term persistent CAR-engineered T cells have not been fully investigated. The fate of CD19-specific (CAR19) T-cells in two leukemia…

J. Joseph Melenhorst, Ph.D., Research Professor of Pathology and Laboratory Medicine Department: Pathology and Laboratory Medicine from the University of Pennsylvania speaks about the ASH 2021 Abstract 166 Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152664.htmlAdoptive transfer of chimeric antigen receptor (CAR)-reprogrammed T cells has shown promise in treating a variety of cancers. In chronic lymphocytic leukemia (CLL), functional persistence of CAR T-cells is a crucial predictor of long-term remissions, although the properties of long-term persistent CAR-engineered T cells have not been fully investigated. The fate of CD19-specific (CAR19) T-cells in two leukemia…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Link to Study:https://clinicaltrials.gov/ct2/show/NCT02620280Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an…

Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.Link to Abstract:https://www.sciencedirect.com/science/article/abs/pii/S0006497121023892#!A summary -Context:While time-limited new agent combinations have shown good overall response rates and long-term responses in patients with chronic lymphocytic leukemia (CLL), they also have a high rate of adverse events and may overtreat many patients who are at low risk. Patients on indefinite ibrutinib monotherapy, on the other hand, are at…

Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.Link to Abstract:https://www.sciencedirect.com/science/article/abs/pii/S0006497121023892#!A summary -Context:While time-limited new agent combinations have shown good overall response rates and long-term responses in patients with chronic lymphocytic leukemia (CLL), they also have a high rate of adverse events and may overtreat many patients who are at low risk. Patients on indefinite ibrutinib monotherapy, on the other hand, are at…

Neha Vapiwala, MD Professor of Radiation Oncology at the Hospital of the University of PennsylvaniaDepartment: Radiation Oncology, Penn Medicine speaks about the From JAMA Oncology – Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34882189/A summary -Significance:It’s unclear how the historical exclusion of women and racial and ethnic minorities from medical school and, as a result, oncologic subspecialties, has influenced faculty diversity in oncology departments over time. Oncologic faculty diversity is a critical strategy for improving cancer care and addressing health inequities in an increasingly diverse US cancer community.Goals:To…